Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

molmed biotech of the week header

From one fashion capital to the other, this week we leave Paris and head down to Milan. Home to some worldwide high-fashion brands, Da Vinci’s Last Supper mural and main city of the Lombardy region, Milan is also where MolMed, our Biotech of the Week, is based.

City: Milan (Italy)

Founded: 1996

Employees: (+/-) 120 (as of 12/2015)

Financial Data: €13.52M Revenues (in 2015)

CEO: Riccardo Palmisano



Mission: MolMed is active in the development, research and clinical validation of novel antitumour therapies. On their pipeline you have two major novel therapeutics in current clinical development: TK, a ex vivo cell therapy, enabling safe HSCT from partially compatible haplo-identical donors (e.g close relatives i.e mother, father, brothers or sisters), who are available for most of all patients and NGR-hTNF, a novel vascular targeting agent, in Phase II in four different indications: colorectal, small-cell lung and liver cancers, and malignant pleural mesothelioma.

Led by current CEO Riccardo Palmisano since December 2015, MolMed is also listed on the Milan stock exchange (market cap +-€150M).

Comment: MolMed is one of the biggest Biotech company in Italy, and their achievements make them a reliable and well-founded choice for our Biotech of the Week.

Explore other topics: CancerItalyMolMed

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.